Oxford BioDynamics Plc, a biotechnology company, recently announced the successful passing of all resolutions proposed at its Annual General Meeting. The company is focused on developing and commercializing precision medicine tests for life-changing diseases. Its flagship products include the EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch® PSE (Prostate Screening test) blood tests. These tests have been launched in various markets, with the CiRT test being a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, and the PSE test boosting the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer.
In addition to these tests, the company has also launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test), and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit. These products are based on the company's proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for the prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.
Oxford BioDynamics has engaged in numerous partnerships with big pharma and leading institutions, including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital, and Mitsubishi Tanabe Pharma. The company has built a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics, and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 15,000 samples in more than 30 human diseases.
Headquartered in Oxford, UK, and listed on AIM of the London Stock Exchange, Oxford BioDynamics also has a commercial office in Gaithersburg and a clinical laboratory in Frederick, MD, USA, and a reference laboratory in Penang, Malaysia.